阿斯利康(AstraZeneca)3月3日宣布,Bydureon Pen(exenatide,艾塞那肽长效缓释注射悬液,2mg)获FDA批准,作为一种辅助药物,结合饮食和运动,用于改善2型糖尿病成人患者的血糖控制。 Bydureon不应用于1型糖尿病或糖尿病痛症酸中毒(diabetic ketoacidosis)的治疗。同时,不建议将Bydureon用于饮食和运动不能充分控制血糖的2型糖...
US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes - European Pharmaceutical ReviewAstraZenecaBriggs Morrison
Bydureon BCise 的批准让我们能够推出一个新的剂型,采用改进的易于使用的设备,这将有助于提高病人的体验。” (2014年批准的Bydureon Pen是一种预填充的一次性笔式注射器) 美国患者将在 2018 年第一季度获取到 Bydureon BCise。目前欧洲药物管理局也接受了这个新的自动注射器装置的评审申请。 (来源:丁香园)...
药品通用名 注射用艾塞那肽微球(预填充笔) 英文名称 Exenatide Powder And Solvent For Prolonged-Release Suspension For Injection In Pre-Filled Pen 商品名 Bydureon 规格 2mg 剂型 注射剂 持证商 Astrazeneca AB 备注1 未进口原研药品 备注2 欧盟上市 来源分类 暂无权限 来源批次 暂无权限 ...
英文别名HSDB 7789 | LY 2148568 | ITCA 650 | AC2993A | Bydureon Pen | DA 3091 | AC 2993 | UNII-9P1872D4OL | Exenatide [USAN:INN:BAN:JAN] | Exendin-4 | Bydureon | C184H282N50O60S | Exenatide | AC002993 | Exenatide; Exendin-4 | Exendin 4 | SCHEMBL14634818 | PT302 ...
The Bydureon pen was discontinued in March 2021 and has been replaced by Bydureon Bcise Autoinjector. The Bydureon Bcise Autoinjector has been designed to be easy to use. There is no need to attach a needle (the hidden needle is already attached) or turn a dial. Always store your Bydureon...
许可产品为Byetta、Bydureon single dose tray、Bydureon dual chamber pen及Bydureon autoinjector,其详情载于独家许可协议。 百泌达和百达扬的前世今生 根据阿斯利康提供的资料,截至2014年12月31日止年度及截至2015年12月31日止年度,许可产品于中国的总收益分别约为1130万美元及1460万美元。
This prevents leaking of the remaining medicine and prevents air bubbles from forming in the pen. Throw away used needles in a hard, closed container where the needles cannot poke through. Keep this container away from children and pets. ...
摘要: 2012年1月,美国FDA批准了Amylin制药有限公司和Alkermes有限公司合作开发的依西那肽(exenatide)控释注射用悬浮液Bydureon,用作饮食和运动疗法的附加药物改善成人2型糖尿病患者的血糖控制水平.依西那肽属胰高血糖素样肽-1受体激动剂,能像人肠促胰岛素胰高血糖素样肽-1一样通过对胃,肝,胰腺和脑的 展开 ...
Bydureon Pen (exenatide) had been due to reach the market at the end of 2012 or in early 2013, but was held up by an FDA request for more data. It will be launched onto the market later this year, said AZ in a statement. The GLP-1 agonist – which is also sold in an immediate...